OncoMatch/Clinical Trials/NCT06905587
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Is NCT06905587 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Methylphenidate (MPH) for brain tumor, pediatric.
Treatment: Methylphenidate (MPH) — Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: treatment for pediatric brain tumor
Treated for a PBT during the previous 10 years, starting from date of diagnosis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06905587 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received treatment for pediatric brain tumor.
Is there an age limit?
Yes. Patients must be 27 years or younger and at least 6 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages